New Long-Term Data from the CHRYSALIS Study Show Median : vi

Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive...

Related Keywords

United States , Belgium , Singapore , Beerse , Region Flamande , Chicago , Illinois , Amsterdam , Noord Holland , Netherlands , South Korea , American , Janssen Cilag Gmb , Martin Vogel , Hoon Lee , Kiran Patel , National Cancer Institute , Janssen Pharmaceutical Companies , American Society Of Clinical Oncology , Samsung Medical Center , European Commission , Exchange Commission , Yuhan Corporation , Johnson , Companies Of Johnson , European Union , American Society For Clinical Oncology Annual Meeting , European Medicines Agency , None Of The Janssen Pharmaceutical Companies , Sungkyunkwan University School Of Medicine , American Lung Association , Janssen Biotech Inc , Drug Administration , Clinical Development , Janssen Research , Janssen Pharmaceutical Companies Of Johnson , Janssen Research Development , Clinical Oncology , Annual Meeting , Sungkyunkwan University School , Predictive Biomarkers , Amivantamaband Lazertinib Combination , Area Lead Oncology , Safety Data , Investigational Use , Vice President , Solid Tumors , Overall Response Rate , Response Evaluation Criteria , Solid Tumors Version , Blinded Independent Central Review , Conditional Marketing Authorisation , Product Characteristics , Thoracic Oncology , Janssen Biotech , Pharmaceutical Companies , Infectious Diseases , Janssen Cilag Gmbh , Janssen Pharmaceutica , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Clinical Oncology Annual , Human Bispecific , Met Antibody , Accessed June , Transduct Target Ther , Practice Guideline , Combination With Amivantamab , National Cancer , Amivantamab Summary , Amivantamab Subcutaneous , Advanced Solid Malignancies , First Treatment Approved , Novel Bispecific Antibody Targeting , Met Is Effective , Resistant Lung , Diverse Models , Met Bispecific Antibody , Induces Receptor Downmodulation , Antitumor Activity , Mol Cancer , Announces New Data Supporting Safety , Lazertinib Combination , Non Small Cell Lung Cancer , Lazertinib Combination Therapy Versus Osimertinib , Locally Advanced , Metastatic Non Small Cell Lung Cancer , Patients With Epidermal Growth Factor Receptor , Mutated Locally Advanced , Cell Lung Cancer After Osimertinib Failure , Combination Amivantamab , Carboplatin Pemetrexed Therapy , Compared With Carboplatin Pemetrexed , Participants With Advanced , Growth Factor Receptor , Mutated Non Small Cell Lung Cancer , Mutated Advanced , Capmatinib Combination Therapy , Patients With Advanced , After Previous , Lung Cancer Res , Mutation Variants , Real World , World Conference , Lung Cancer Annual Meeting , Year Survival , Mutant Metastatic Lung Adenocarcinoma Treated , Janssen Emea ,